NCT00216125 - Cisplatin/Etoposide/Radiotherapy +/- Consolidation Docetaxel in Advanced Stage III Non-Small Cell Lung Cancer | Biotech Hunter

Enrollment

243

Participants

Timeline

Start Date

February 28, 2002

Primary Completion Date

June 30, 2006

Study Completion Date

March 31, 2008

Conditions

Non-Small Cell Lung Cancer

Interventions

DRUG

Cisplatin

Cisplatin 50 mg/m2 day 1, 8, 29, 36

DRUG

Etoposide

Etoposide 50 mg/m2, days 1-5, 29-33

RADIATION

Radiation

Radiation 5940 cGy (180 cGy/day)

DRUG

Docetaxel

docetaxel 75mg/m2 q3wk x 3 cycles

Trial Locations (15)

46202

Indiana University Cancer Center, Indianapolis

Quality Cancer Center (MCGOP), Indianapolis

46256

Community Regional Cancer Center, Indianapolis

46515

Elkhart Clinic, Elkhart

46527

Center for Cancer Care at Goshen Health System, Goshen

46601

Northern Indiana Cancer Research Consortium, South Bend

46815

Fort Wayne Oncology & Hematology, Inc, Fort Wayne

47150

Center for Cancer Care, Inc., P.C., New Albany

47303

Medical Consultants, P.C., Muncie

47714

Oncology Hematology Associates of SW Indiana, Evansville

47804

AP&S Clinic, Terre Haute

61401

Medical & Surgical Specialists, LLC, Galesburg

63110

Siteman Cancer Center, St Louis

68114

Methodist Cancer Center, Omaha

77060

US Oncology, Houston